Sander Flaum

Looking past COVID, the medical world is in turmoil. It’s hard enough for us in manufacturing and marketing to keep up with innovative technologies. Patients and caregivers have it especially tough since they are on the brunt end of disruptive innovations. Every day, patients face a ceaseless onslaught of sort of truths, half-truths, and flat-out lies about their healthcare, and HCPs no sooner graduate from med school than they discover much of their training is obsolete. Flaum Navigators Principal Sander A. Flaum explores how we can engage patients and physicians in the “Next Big Thing.”

      OpGen Subsidiary Ares Genetics Launches AREScloud AREScloud is a new, commercial web application aimed at accelerating the analysis of sequenced clinical isolates AREScloud offers an advanced solution for infection prevention and control ROCKVILLE, Md., Oct. 21, 2021 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power […]

Researchers at the National Autonomous University of Mexico (UNAM) created a facemask using silver and copper nanolayers that neutralizes SARS-CoV-2, the virus that causes Covid-19, the university’s official gazette said on Aug. 26.

Pfizer is expanding the company’s presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and the lead antifungal compound Fosmanogepix (APX001).

None of the 43 antibiotics in development as well as recently approved medicines are enough to combat the increasing emergence and spread of antimicrobial resistance, the World Health Organization cautioned on April 15.

The U.S. Food and Drug Administration approved a supplemental New Drug Application for Shionogi & Co. Ltd.’s Fetroja (cefiderocol) for the treatment of patients 18 years of age or older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

The deadly fungal infection Candida auris reared its head iin a Los Angeles healthcare facility and could be related to Covid-19 cases through the conservation of personal protective equipment strategies. Amplyx Pharmaceuticals is working to develop a first-line treatment for patients with invasive fungal infections caused by Candida.

BioSpace provided an update on recent personnel movement within the healthcare industry, including Cheryl R. Blanchard being named president and chief executive officer of Anika Therapeutics.

Leading scientists, public policy experts and biotech industry leaders joined forces to launch “Working to Fight AMR,” a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance.

Merix Pharmaceutical Corp. announced the company’s proprietary botanical extract formula VIRACEA was found to be highly active against HSV-1 and HSV-2 in laboratory testing.